UK markets closed

Qualigen Therapeutics, Inc. (7R9.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.1820+0.0780 (+75.00%)
At close: 11:40AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/03/2020
Total revenue
0
0
0
5,654
5,558
Cost of revenue
-
-
4,303
4,332
3,978
Gross profit
-
-
680.801
1,321
1,580
Operating expenses
Research development
5,209
5,209
4,486
11,717
1,205
Selling general and administrative
6,096
6,096
10,275
12,268
1,878
Total operating expenses
11,305
11,305
14,761
23,984
3,083
Operating income or loss
-11,305
-11,305
-14,761
-22,663
-1,503
Interest expense
1,525
1,525
34.397
-
283.095
Total other income/expenses net
349.776
349.776
907.203
4,729
2.785
Income before tax
-12,480
-12,480
-13,888
-17,892
-1,784
Income tax expense
-4.793
-4.793
6.548
5.427
4
Income from continuing operations
-12,475
-12,475
-13,894
-17,897
-1,788
Net income
-13,417
-13,417
-18,641
-17,897
-1,788
Net income available to common shareholders
-13,417
-13,417
-18,641
-17,897
-1,788
Basic EPS
-3.73
-2.65
-4.86
-6.10
-1.43
Diluted EPS
-3.73
-2.65
-4.86
-6.10
-1.43
Basic average shares
4,820
5,073
3,840
2,933
1,254
Diluted average shares
4,820
5,073
3,840
2,933
1,254